

SENATE No. 2512

The Commonwealth of Massachusetts

In the One Hundred and Ninety-Third General Court
(2023-2024)

1 in section 21, by inserting, in line 196, after the word “drugs”, the following words:-

2 “, continuous glucose monitoring system components, all components of the continuous
3 glucose monitoring system of which the component is a part, and, when applicable, delivery
4 devices,”; and

5 in said section 21, by adding, in line 413, after the word “barriers.”, the following words:

6 “This section shall also apply to selected continuous glucose monitoring system
7 components, all components of the continuous glucose monitoring system of which the
8 component is a part, and delivery devices, when applicable.”; and

9 in section 39, by inserting, in line 627, after the word “all”, the following words:-

10 “continuous glucose monitoring system components, all components of the continuous
11 glucose monitoring system of which the component is a part, and”; and

12 in section 41, by adding, after the definition of “Brand name drug”, the following
13 definitions:-

14 ““Continuous glucose monitoring system”, a system to continuously sense, transmit, and
15 display blood glucose levels.

16 “Continuous glucose monitoring system component”, a component of a system to
17 continuously monitor blood glucose levels such as a sensor, transmitter, or display.”; and
18 in said section 41, by adding, after the definition of “Delivery device”, the following
19 definition:-

20 ““Diabetes treatment supplies”, supplies for the treatment of diabetes including, but not
21 limited to, syringes, needles, blood glucose monitors, blood glucose monitoring strips for home
22 use, strips to calibrate continuous blood glucose monitors, urine glucose strips, ketone strips,
23 lancets, adhesive skin patches, insulin pump supplies, voice-synthesizers for blood glucose
24 monitors for use by the legally blind, visual magnifying aids for use by the legally blind;
25 provided further that “associated supplies” shall not include a brand name drug, a generic drug, a
26 continuous glucose monitoring system component, or a delivery device.”; and

27 in said section 41, by inserting, in line 691, after the word “color”, the following words:-

28 “; provided, however, that for diabetes, the commission shall also select a continuous
29 glucose monitoring system component”; and

30 in said section 41, by striking out, in lines 699 to 700, the words “and delivery device,
31 when applicable”; and

32 in said section 41, by striking out subsection (d) and inserting in place thereof the
33 following subsection:-

34 “(d) The continuous glucose monitoring system component shall be selected in the same
35 manner in which the 1 generic drug and 1 brand name drug are selected.”; and

36 in said section 41, by striking out subsection (e) and inserting in place thereof the
37 following subsection:-

38 “(e)(1) The commission shall provide coverage for the brand name drugs and generic
39 drugs selected pursuant to subsection (b). Coverage for the selected generic drugs shall not be
40 subject to any cost-sharing, including co-payments and co-insurance, and shall not be subject to
41 any deductible. Coverage for selected brand name drugs shall not be subject to any deductible or
42 co-insurance and any co-payment shall not exceed \$25 per 30-day supply; provided, however,
43 that nothing in this section shall prevent co-payments for a 30-day supply of the selected brand
44 name drugs from being reduced below the amount specified in this section.

45 (2) If use of a brand name drug or generic drug that the commission selects requires a
46 separate delivery device, the commission shall select a delivery device for that drug in
47 accordance with the factors established in subsection (c) for selecting brand name drugs and
48 generic drugs, to the extent possible. The commission shall provide coverage for the delivery
49 device, and the delivery device shall not be subject to any cost-sharing, including co-payments
50 and co-insurance, and shall not be subject to any deductible.

51 (3) The commission shall provide coverage for the continuous glucose monitoring system
52 component selected pursuant to subsection (b), and all components of the blood glucose
53 monitoring system of which the selected component is a part. All components of the applicable
54 continuous glucose monitoring system shall not be subject to any cost-sharing, including co-
55 payments and co-insurance, and shall not be subject to any deductible.

56 (4) The commission shall provide coverage for necessary diabetes treatment supplies.
57 Such supplies shall not be subject to any cost-sharing, including co-payments and co-insurance,
58 and shall not be subject to any deductible.” and;

59 in said section 41, by striking out, in lines 743 to 744, the sentence “When applicable this
60 subsection shall apply to delivery devices.”, and inserting in place thereof the following
61 sentence:-

62 “This subsection shall apply to continuous glucose monitoring system components and,
63 when applicable, delivery devices.”; and

64 in said section 41, by adding, in line 755, after the words “subsection (b).”, the following
65 words:-

66 “This subsection shall apply to continuous glucose monitoring system components and,
67 when applicable, delivery devices.”

68 in said section 41, by inserting, in line 758, after the word “drug”, the following words:-

69 “, continuous glucose monitoring system component”; and

70 in said section 41, by striking out, in line 759, the words “subsection (d)”, and inserting in
71 place thereof the following words:-

72 “subsection (e)”; and

73 in said section 41, by striking out, in lines 767 and 769, the words “and delivery devices”
74 each time those words appear; and

75 in said subsection 41, by adding, in line 772, after the word “made.”, the following
76 words:-

77 “This subsection shall apply to continuous glucose monitoring system components and,
78 when applicable, delivery devices, in the same manner in which it applies to drugs.”; and

79 in said section 41, by striking out, in line 773, the words “drugs and delivery devices”,
80 and inserting in place thereof the following words:-

81 “drugs, continuous glucose monitoring system components, all components of the system
82 of which the component is a part and delivery devices”; and

83 in section 44, by adding, after the definition of “Brand name drug”, the following
84 definitions:-

85 ““Continuous glucose monitoring system”, a system to continuously sense, transmit, and
86 display blood glucose levels.

87 “Continuous glucose monitoring system component”, a component of a system to
88 continuously monitor blood glucose levels such as a sensor, transmitter, or display.”; and

89 in said section 44, by adding, after the definition of “Delivery device”, the following
90 definition:-

91 ““Diabetes treatment supplies”, supplies for the treatment of diabetes including, but not
92 limited to, syringes, needles, blood glucose monitors, blood glucose monitoring strips for home
93 use, strips to calibrate continuous blood glucose monitors, urine glucose strips, ketone strips,
94 lancets, adhesive skin patches, insulin pump supplies, voice-synthesizers for blood glucose
95 monitors for use by the legally blind, visual magnifying aids for use by the legally blind;

96 provided further that “associated supplies” shall not include a brand name drug, a generic drug, a
97 continuous glucose monitoring system component, or a delivery device.”; and

98 in said section 44, by inserting, in line 891, after the word “color”, the following words:-

99 “; provided, however, that for diabetes, the division shall also select a continuous glucose
100 monitoring system component”; and

101 in said section 44, by striking out subsection (d) and inserting in place thereof the
102 following subsection:-

103 “(d) The continuous glucose monitoring system component shall be selected in the same
104 manner in which the 1 generic drug and 1 brand name drug are selected.”; and

105 in said section 44, by striking out subsection (e) and inserting in place thereof the
106 following subsection:-

107 “(e)(1) The division shall provide coverage for the brand name drugs and generic drugs
108 selected pursuant to subsection (b). Coverage for the selected generic drugs shall not be subject
109 to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any
110 deductible. Coverage for selected brand name drugs shall not be subject to any deductible or co-
111 insurance and any co-payment shall not exceed \$25 per 30-day supply; provided, however, that
112 nothing in this section shall prevent co-payments for a 30-day supply of the selected brand name
113 drugs from being reduced below the amount specified in this section.

114 (2) If use of a brand name drug or generic drug that the division selects requires a
115 separate delivery device, the division shall select a delivery device for that drug in accordance
116 with the factors established in subsection (c) for selecting brand name drugs and generic drugs,

117 to the extent possible. The division shall provide coverage for the delivery device, and the
118 delivery device shall not be subject to any cost-sharing, including co-payments and co-insurance,
119 and shall not be subject to any deductible.

120 (3) The division shall provide coverage for the continuous glucose monitoring system
121 component selected pursuant to subsection (b), and all components of the blood glucose
122 monitoring system of which the selected component is a part. All components of the applicable
123 continuous glucose monitoring system shall not be subject to any cost-sharing, including co-
124 payments and co-insurance, and shall not be subject to any deductible.

125 (4) The division shall provide coverage for necessary diabetes treatment supplies. Such
126 supplies shall not be subject to any cost-sharing, including co-payments and co-insurance, and
127 shall not be subject to any deductible.”; and

128 in said section 44, by striking out, in lines 944 to 945, the sentence “When applicable this
129 subsection shall apply to delivery devices.”, and inserting in place thereof the following
130 sentence:-

131 “This subsection shall apply to continuous glucose monitoring system components and,
132 when applicable, delivery devices.”; and

133 in said section 44, by adding, in line 958, after the words “subsection (b).”, the following
134 words:-

135 “This subsection shall apply to continuous glucose monitoring system components and,
136 when applicable, delivery devices.”; and

137 in said section 44, by inserting, in line 960, after the word “drug”, the following words:-

138 “, continuous glucose monitoring system component”; and

139 in said section 44, by striking out, in line 961, the words “subsection (d)”, and inserting in
140 place thereof the following words:-

141 “subsection (e)”; and

142 in said section 44, by striking out, in lines 972, the words “and delivery devices”; and

143 in said subsection 44, by adding, in line 975, after the word “made.”, the following
144 words:-

145 “This subsection shall apply to continuous glucose monitoring system components and,
146 when applicable, delivery devices, in the same manner in which it applies to drugs.”; and

147 in said section 44, by striking out, in line 976, the words “drugs and delivery devices”,
148 and inserting in place thereof the following words:-

149 “drugs, continuous glucose monitoring system components, all components of the system
150 of which the component is a part and delivery devices”; and

151 in section 45, by adding, after the definition of “Brand name drug”, the following
152 definitions:-

153 ““Continuous glucose monitoring system”, a system to continuously sense, transmit, and
154 display blood glucose levels.

155 “Continuous glucose monitoring system component”, a component of a system to
156 continuously monitor blood glucose levels such as a sensor, transmitter, or display.”; and

157 in said section 45, by adding, after the definition of “Delivery device”, the following
158 definition:-

159 ““Diabetes treatment supplies”, supplies for the treatment of diabetes including, but not
160 limited to, syringes, needles, blood glucose monitors, blood glucose monitoring strips for home
161 use, strips to calibrate continuous blood glucose monitors, urine glucose strips, ketone strips,
162 lancets, adhesive skin patches, insulin pump supplies, voice-synthesizers for blood glucose
163 monitors for use by the legally blind, visual magnifying aids for use by the legally blind;
164 provided further that “associated supplies” shall not include a brand name drug, a generic drug, a
165 continuous glucose monitoring system component, or a delivery device.”; and

166 in said section 45, by inserting, in line 1012, after the word “color”, the following words:-

167 “; provided, however, that for diabetes, the carrier shall also select a continuous glucose
168 monitoring system component”; and

169 in said section 45, by striking out subsection (d) and inserting in place thereof the
170 following subsection:-

171 “(d) The continuous glucose monitoring system component shall be selected in the same
172 manner in which the 1 generic drug and 1 brand name drug are selected.”; and

173 in said section 45, by striking out subsection (e) and inserting in place thereof the
174 following subsection:-

175 “(e)(1) The carrier shall provide coverage for the brand name drugs and generic drugs
176 selected pursuant to subsection (b). Coverage for the selected generic drugs shall not be subject
177 to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any

178 deductible. Coverage for selected brand name drugs shall not be subject to any deductible or co-
179 insurance and any co-payment shall not exceed \$25 per 30-day supply; provided, however, that
180 nothing in this section shall prevent co-payments for a 30-day supply of the selected brand name
181 drugs from being reduced below the amount specified in this section.

182 (2) If use of a brand name drug or generic drug that the carrier selects requires a separate
183 delivery device, the carrier shall select a delivery device for that drug in accordance with the
184 factors established in subsection (c) for selecting brand name drugs and generic drugs, to the
185 extent possible. The carrier shall provide coverage for the delivery device, and the delivery
186 device shall not be subject to any cost-sharing, including co-payments and co-insurance, and
187 shall not be subject to any deductible.

188 (3) The carrier shall provide coverage for the continuous glucose monitoring system
189 component selected pursuant to subsection (b), and all components of the blood glucose
190 monitoring system of which the selected component is a part. All components of the applicable
191 continuous glucose monitoring system shall not be subject to any cost-sharing, including co-
192 payments and co-insurance, and shall not be subject to any deductible.

193 (4) The carrier shall provide coverage for necessary diabetes treatment supplies. Such
194 supplies shall not be subject to any cost-sharing, including co-payments and co-insurance, and
195 shall not be subject to any deductible.”; and

196 in said section 45, by striking out, in lines 1064, the sentence “When applicable this
197 subsection shall apply to delivery devices.”, and inserting in place thereof the following
198 sentence:-

199 “This subsection shall apply to continuous glucose monitoring system components and,
200 when applicable, delivery devices.”; and

201 in said section 45, by adding, in line 1075, after the words “subsection (b).”, the
202 following words:-

203 “This subsection shall apply to continuous glucose monitoring system components and,
204 when applicable, delivery devices.”; and

205 in said section 45, by inserting, in line 1077, after the word “drug”, the following words:-

206 “, continuous glucose monitoring system component”; and

207 in said section 45, by striking out, in line 1079, the words “subsection (d)”, and inserting
208 in place thereof the following words:-

209 “subsection (e)”; and

210 in said section 45, by striking out, in lines 1087 and 1089, the words “and delivery
211 devices”, each time they appear; and

212 in said subsection 45, by adding, in line 1092, after the word “made.”, the following
213 words:-

214 “This subsection shall apply to continuous glucose monitoring system components and,
215 when applicable, delivery devices, in the same manner in which it applies to drugs.”; and

216 in said section 45, by striking out, in line 1093, the words “drugs and delivery devices”,
217 and inserting in place thereof the following words:-

218 “drugs, continuous glucose monitoring system components, all components of the system
219 of which the component is a part and delivery devices”; and

220 in section 47, by adding, after the definition of “Brand name drug”, the following
221 definitions:-

222 ““Continuous glucose monitoring system”, a system to continuously sense, transmit, and
223 display blood glucose levels.

224 “Continuous glucose monitoring system component”, a component of a system to
225 continuously monitor blood glucose levels such as a sensor, transmitter, or display.”; and

226 in said section 47, by adding, after the definition of “Delivery device”, the following
227 definition:-

228 ““Diabetes treatment supplies”, supplies for the treatment of diabetes including, but not
229 limited to, syringes, needles, blood glucose monitors, blood glucose monitoring strips for home
230 use, strips to calibrate continuous blood glucose monitors, urine glucose strips, ketone strips,
231 lancets, adhesive skin patches, insulin pump supplies, voice-synthesizers for blood glucose
232 monitors for use by the legally blind, visual magnifying aids for use by the legally blind;
233 provided further that “associated supplies” shall not include a brand name drug, a generic drug, a
234 continuous glucose monitoring system component, or a delivery device.”; and

235 in said section 47, by adding, in line 1144, after the word “conditions”, the following
236 words:-

237 “: (i) diabetes; (ii) asthma; and (iii) heart conditions, including, but not limited to, those
238 conditions that disproportionately impact a particular demographic group, including people of

239 color; provided, however, that for diabetes, the carrier shall also select a continuous glucose
240 monitoring system component”; and

241 in said section 47, by striking out subsection (d) and inserting in place thereof the
242 following subsection:-

243 “(d) The continuous glucose monitoring system component shall be selected in the same
244 manner in which the 1 generic drug and 1 brand name drug are selected.”; and

245 in said section 47, by striking out subsection (e) and inserting in place thereof the
246 following subsection:-

247 “(e)(1) The carrier shall provide coverage for the brand name drugs and generic drugs
248 selected pursuant to subsection (b). Coverage for the selected generic drugs shall not be subject
249 to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any
250 deductible. Coverage for selected brand name drugs shall not be subject to any deductible or co-
251 insurance and any co-payment shall not exceed \$25 per 30-day supply; provided, however, that
252 nothing in this section shall prevent co-payments for a 30-day supply of the selected brand name
253 drugs from being reduced below the amount specified in this section.

254 (2) If use of a brand name drug or generic drug that the carrier selects requires a separate
255 delivery device, the carrier shall select a delivery device for that drug in accordance with the
256 factors established in subsection (c) for selecting brand name drugs and generic drugs, to the
257 extent possible. The carrier shall provide coverage for the delivery device, and the delivery
258 device shall not be subject to any cost-sharing, including co-payments and co-insurance, and
259 shall not be subject to any deductible.

260 (3) The carrier shall provide coverage for the continuous glucose monitoring system
261 component selected pursuant to subsection (b), and all components of the blood glucose
262 monitoring system of which the selected component is a part. All components of the applicable
263 continuous glucose monitoring system shall not be subject to any cost-sharing, including co-
264 payments and co-insurance, and shall not be subject to any deductible.

265 (4) The carrier shall provide coverage for necessary diabetes treatment supplies. Such
266 supplies shall not be subject to any cost-sharing, including co-payments and co-insurance, and
267 shall not be subject to any deductible.”; and

268 in said section 47, by striking out, in line 1196, the sentence “When applicable this
269 subsection shall apply to delivery devices”, and inserting in place thereof the following
270 sentence:-

271 “This subsection shall apply to continuous glucose monitoring system components and,
272 when applicable, delivery devices.”; and

273 in said section 47, by adding, in line 1207, after the words “subsection (b).”, the
274 following words:-

275 “This subsection shall apply to continuous glucose monitoring system components and,
276 when applicable, delivery devices.”; and

277 in said section 47, by inserting, in line 1209, after the word “drug”, the following words:-

278 “, continuous glucose monitoring system component”; and

279 in said section 47, by striking out, in line 1211, the words “subsection (d)”, and inserting
280 in place thereof the following words:-

281 “subsection (e)”; and

282 in said section 47, by striking out, in lines 1219 and 1221, the words “and delivery
283 devices” each time they appear; and

284 in said subsection 47, by adding, in line 1224, after the word “made.”, the following
285 words:-

286 “This subsection shall apply to continuous glucose monitoring system components and,
287 when applicable, delivery devices, in the same manner in which it applies to drugs.”; and

288 in said section 47, by striking out, in line 1225, the words “drugs and delivery devices”,
289 and inserting in place thereof the following words:-

290 “drugs, continuous glucose monitoring system components, all components of the system
291 of which the component is a part and delivery devices”; and

292 in section 48, by adding, after the definition of “Brand name drug”, the following
293 definitions:-

294 ““Continuous glucose monitoring system”, a system to continuously sense, transmit, and
295 display blood glucose levels.

296 “Continuous glucose monitoring system component”, a component of a system to
297 continuously monitor blood glucose levels such as a sensor, transmitter, or display.”; and

298 in said section 48, by adding, after the definition of “Delivery device”, the following
299 definition:-

300 ““Diabetes treatment supplies”, supplies for the treatment of diabetes including, but not
301 limited to, syringes, needles, blood glucose monitors, blood glucose monitoring strips for home
302 use, strips to calibrate continuous blood glucose monitors, urine glucose strips, ketone strips,
303 lancets, adhesive skin patches, insulin pump supplies, voice-synthesizers for blood glucose
304 monitors for use by the legally blind, visual magnifying aids for use by the legally blind;
305 provided further that “associated supplies” shall not include a brand name drug, a generic drug, a
306 continuous glucose monitoring system component, or a delivery device.”; and

307 in said section 48, by inserting, in line 1261, after the word “color”, the following words:-

308 “; provided, however, that for diabetes, the carrier shall also select a continuous glucose
309 monitoring system component”; and

310 in said section 48, by striking out subsection (d) and inserting in place thereof the
311 following subsection:-

312 “(d) The continuous glucose monitoring system component shall be selected in the same
313 manner in which the 1 generic drug and 1 brand name drug are selected.”; and

314 in said section 48, by striking out subsection (e) and inserting in place thereof the
315 following subsection:-

316 “(e)(1) The carrier shall provide coverage for the brand name drugs and generic drugs
317 selected pursuant to subsection (b). Coverage for the selected generic drugs shall not be subject
318 to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any
319 deductible. Coverage for selected brand name drugs shall not be subject to any deductible or co-
320 insurance and any co-payment shall not exceed \$25 per 30-day supply; provided, however, that

321 nothing in this section shall prevent co-payments for a 30-day supply of the selected brand name
322 drugs from being reduced below the amount specified in this section.

323 (2) If use of a brand name drug or generic drug that the carrier selects requires a separate
324 delivery device, the carrier shall select a delivery device for that drug in accordance with the
325 factors established in subsection (c) for selecting brand name drugs and generic drugs, to the
326 extent possible. The carrier shall provide coverage for the delivery device, and the delivery
327 device shall not be subject to any cost-sharing, including co-payments and co-insurance, and
328 shall not be subject to any deductible.

329 (3) The carrier shall provide coverage for the continuous glucose monitoring system
330 component selected pursuant to subsection (b), and all components of the blood glucose
331 monitoring system of which the selected component is a part. All components of the applicable
332 continuous glucose monitoring system shall not be subject to any cost-sharing, including co-
333 payments and co-insurance, and shall not be subject to any deductible.

334 (4) The carrier shall provide coverage for necessary diabetes treatment supplies. Such
335 supplies shall not be subject to any cost-sharing, including co-payments and co-insurance, and
336 shall not be subject to any deductible.”; and

337 in said section 48, by striking out, in lines 1313, the sentence “When applicable this
338 subsection shall apply to delivery devices”, and inserting in place thereof the following
339 sentence:-

340 “This subsection shall apply to continuous glucose monitoring system components and,
341 when applicable, delivery devices”; and

342 in said section 48, by adding, in line 1324, after the words “subsection (b).”, the
343 following words:-

344 “This subsection shall apply to continuous glucose monitoring system components and,
345 when applicable, delivery devices.”

346 in said section 48, by inserting, in line 1326, after the word “drug”, the following words:-

347 “, continuous glucose monitoring system component”; and

348 in said section 48, by striking out, in line 1328, the words “subsection (d)”, and inserting
349 in place thereof the following words:-

350 “subsection (e)”; and

351 in said section 48, by striking out, in lines 1336 and 1338, the words “and delivery
352 devices” each time they appear; and

353 in said subsection 48, by adding, in line 1341, after the word “made.”, the following
354 words:-

355 “This subsection shall apply to continuous glucose monitoring system components and,
356 when applicable, delivery devices, in the same manner in which it applies to drugs.”; and

357 in said section 48, by striking out, in line 1342, the words “drugs and delivery devices”,
358 and inserting in place thereof the following words:-

359 “drugs, continuous glucose monitoring system components, all components of the system
360 of which the component is a part and delivery devices”; and

361 in section 52, by adding, after the definition of “Brand name drug”, the following
362 definitions:-

363 ““Continuous glucose monitoring system”, a system to continuously sense, transmit, and
364 display blood glucose levels.

365 “Continuous glucose monitoring system component”, a component of a system to
366 continuously monitor blood glucose levels such as a sensor, transmitter, or display.”; and

367 in said section 52, by adding, after the definition of “Delivery device”, the following
368 definition:-

369 ““Diabetes treatment supplies”, supplies for the treatment of diabetes including, but not
370 limited to, syringes, needles, blood glucose monitors, blood glucose monitoring strips for home
371 use, strips to calibrate continuous blood glucose monitors, urine glucose strips, ketone strips,
372 lancets, adhesive skin patches, insulin pump supplies, voice-synthesizers for blood glucose
373 monitors for use by the legally blind, visual magnifying aids for use by the legally blind;
374 provided further that “associated supplies” shall not include a brand name drug, a generic drug, a
375 continuous glucose monitoring system component, or a delivery device.”; and

376 in said section 52, by inserting, in line 1394, after the word “color”, the following words:-

377 “; provided, however, that for diabetes, the carrier shall also select a continuous glucose
378 monitoring system component”; and

379 in said section 52, by striking out subsection (d) and inserting in place thereof the
380 following subsection:-

381 “(d) The continuous glucose monitoring system component shall be selected in the same
382 manner in which the 1 generic drug and 1 brand name drug are selected.”; and

383 in said section 52, by striking out subsection (e) and inserting in place thereof the
384 following subsection:-

385 “(e)(1) The carrier shall provide coverage for the brand name drugs and generic drugs
386 selected pursuant to subsection (b). Coverage for the selected generic drugs shall not be subject
387 to any cost-sharing, including co-payments and co-insurance, and shall not be subject to any
388 deductible. Coverage for selected brand name drugs shall not be subject to any deductible or co-
389 insurance and any co-payment shall not exceed \$25 per 30-day supply; provided, however, that
390 nothing in this section shall prevent co-payments for a 30-day supply of the selected brand name
391 drugs from being reduced below the amount specified in this section.

392 (2) If use of a brand name drug or generic drug that the carrier selects requires a separate
393 delivery device, the carrier shall select a delivery device for that drug in accordance with the
394 factors established in subsection (c) for selecting brand name drugs and generic drugs, to the
395 extent possible. The carrier shall provide coverage for the delivery device, and the delivery
396 device shall not be subject to any cost-sharing, including co-payments and co-insurance, and
397 shall not be subject to any deductible.

398 (3) The carrier shall provide coverage for the continuous glucose monitoring system
399 component selected pursuant to subsection (b), and all components of the blood glucose
400 monitoring system of which the selected component is a part. All components of the applicable
401 continuous glucose monitoring system shall not be subject to any cost-sharing, including co-
402 payments and co-insurance, and shall not be subject to any deductible.

403 (4) The carrier shall provide coverage for necessary diabetes treatment supplies. Such
404 supplies shall not be subject to any cost-sharing, including co-payments and co-insurance, and
405 shall not be subject to any deductible.”; and

406 in said section 52, by striking out, in line 1446, the sentence “When applicable this
407 subsection shall apply to delivery devices.”, and inserting in place thereof the following
408 sentence:-

409 “This subsection shall apply to continuous glucose monitoring system components and,
410 when applicable, delivery devices.”; and

411 in said section 52, by adding, in line 1457, after the words “subsection (b).”, the
412 following words:-

413 “This subsection shall apply to continuous glucose monitoring system components and,
414 when applicable, delivery devices.”

415 in said section 52, by inserting, in line 1459, after the word “drug”, the following words:-

416 “, continuous glucose monitoring system component”; and

417 in said section 52, by striking out, in line 1441, the words “subsection (d)”, and inserting
418 in place thereof the following words:-

419 “subsection (e)”; and

420 in said section 52, by striking out, in lines 1469 and 1471, the words “and delivery
421 devices” each time they appear; and

422 in said subsection 52, by adding, in line 1474, after the word “made.”, the following
423 words:-

424 “This subsection shall apply to continuous glucose monitoring system components and,
425 when applicable, delivery devices, in the same manner in which it applies to drugs.”; and

426 in said section 52, by striking out, in line 1475, the words “drugs and delivery devices”,
427 and inserting in place thereof the following words:-

428 “drugs, continuous glucose monitoring system components, all components of the system
429 of which the component is a part and delivery devices”; and

430 in section 61, by adding, in line 1790, after the word “website.”, the following words:-

431 “This section shall also apply to selected continuous glucose monitoring system
432 components and, when applicable, delivery devices.”